[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![_Investor_Feed_ Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1825090112713285632.png) Investor Feed [@_Investor_Feed_](/creator/twitter/_Investor_Feed_) on x 6145 followers
Created: 2025-07-25 08:06:31 UTC

Cipla Q1FY26 Highlights: Strong Growth, ESG Progress & U.S. Biosimilar Launch Ahead 💊📈 | MCap 1,20,944.59 Cr

- Q1FY26 revenue: ₹6,957 Cr (+3.9% YoY)
- EBITDA: ₹1,778 Cr (25.6% margin, slight X bps decline YoY)
- PAT: ₹1,298 Cr (+10.2% YoY, XXXX% margin)
- India segment record: ₹3,070 Cr (first ₹3,000+ Cr Q1)
- North America revenue: $XXX Mn (Albuterol X in U.S. with XXXX% share)
- Africa growth: 1.5x market rate, $XXX Mn in South Africa (+11% YoY)
- Emerging Markets/Europe: $XXX Mn (+8% YoY)
- R&D spend: ₹432 Cr (6.2% of revenue)
- Net cash position: ₹10,379 Cr (June 2025)
- Key launches: Nano Paclitaxel (ANDA) & Nilotinib Capsules (NDA)
- U.S. biosimilar launch planned for Q2 FY26
- ESG: XX% Scope X & X emissions cut, 1.75x water positive
- India ops: Zero Waste to Landfill, XX% renewable energy
- Safety: X manufacturing fatalities in FY24-25 (goal: zero)
- Supplier ESG assessments: XX% of procurement spend

Complete Source:

Disc: Information provided in this tweet can be inaccurate, verify through the source before making any investment decision.

Preview 👇 (First X out of XX pages)

![](https://pbs.twimg.com/media/GwsEPSfa4AAjB5W.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1948656092533203219/c:line.svg)

**Related Topics**
[united states](/topic/united-states)
[india](/topic/india)
[mcap](/topic/mcap)
[esg](/topic/esg)
[$ciplans](/topic/$ciplans)
[investment](/topic/investment)

[Post Link](https://x.com/_Investor_Feed_/status/1948656092533203219)